Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brands: Etrafon, Trilafon
Published 2025-09-19 · Last reviewed 2025-09-26 · 5 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Perphenazine is a mid-potency phenothiazine antipsychotic with efficacy comparable to SGAs at moderate doses and lower metabolic risk.
Used for adult schizophrenia; no depot formulation is available, so adherence planning (pill boxes, supervised dosing, pharmacy packaging) matters when selecting perphenazine.
The core trade-off is metabolic advantage versus movement-disorder risk (EPS and tardive dyskinesia). Shared decision-making often includes a plan for early symptoms (restlessness, stiffness, tremor) and how to seek help promptly.
The compare view and the Perphenazine evidence feed can help contextualize EPS risk, metabolic trade-offs, and formulation constraints when switching from SGAs.
CATIE trial revived interest due to comparable efficacy to several SGAs with lower metabolic burden, though EPS and tardive dyskinesia risks persist. Perphenazine is often considered when cost or metabolic concerns limit SGA use; ongoing reassessment for dose minimization or alternative agents is common if movement symptoms emerge.
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
Antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors, blending FGA potency with modest serotonergic effects.
Additional antagonism at histamine H1, adrenergic α1, and muscarinic receptors drives sedation, hypotension, and anticholinergic effects.
Relative to high-potency FGAs (haloperidol), perphenazine’s mixed receptor profile can reduce severe dystonia risk but increases sedation/orthostasis in some patients—dose timing and slow titration improve tolerability.
Perphenazine’s value proposition is affordability with lower metabolic burden; monitoring focuses on movement disorders, orthostasis/sedation, and targeted cardiac safety in higher-risk settings.